Bleeding from staple line erosion after esophageal transection: Effect of omeprazole

Graham L. Kaye, P. Aiden McCormick, Sebastiano Siringo, Kenneth E. F. Hobbs, Neil McIntyre, Andrew K. Burroughs – 1 June 1992 – Esophageal staple transection effectively controls acute variceal bleeding, but up to 50% of these patients will have recurrent upper gastrointestinal bleeding. In our experience, most of these bleeding episodes are caused by total or partial circumferential ulceration at the level of the staple transection: staple line erosion. It caused rebleeding in 29 (40%) of our patients.

Modification of the amount of cholesterol in hepatic steatosis induced in susceptible and resistant mice infected with MHV3: A biochemical and ultrastructural study

Annick Bingen, Jean‐Pierre Martin, François Klein, Marcia Pessah – 1 June 1992 – A mouse hepatitis virus‐3 strain subcultured in our laboratory is a unique experimental model in which to study virus‐induced liver steatosis. This strain produces massive lipid deposition not only in sensitive adult BALB/c mice but also (though less extensive) in virus‐resistant adult A/J mice.

Adenosine receptor blockade reduces splanchnic hyperemia in cirrhotic rats

Samuel S. Lee, E. Lisa Chilton, Jung‐Min Pak – 1 June 1992 – To explore a possible role for adenosine in the pathogenesis of the splanchnic hyperemia of cirrhosis, we administered 8‐phenyltheophylline, a specific adenosine receptor antagonist, to rats with biliary cirrhosis caused by bile duct ligation and to control shamoperated rats. Micro‐Doppler flow studies showed that a 10‐μmol/kg dose of 8‐phenyltheophylline completely abolished the superior mesenteric hyperemic response to infusions of exogenous adenosine in both cirrhotic and control rats.

Intracellular calcium as a second messenger for human hepatocyte growth factor in hepatocytes

Akira Kaneko, Norio Hayashi, Hirohito Tsubouchi, Yuji Tanaka, Toshifumi Ito, Yutaka Sasaki, Hideyuki Fusamoto, Yasushi Daikuhara, Takenobu Kamada – 1 June 1992 – Human hepatocyte growth factor is a newly discovered substance that stimulates DNA synthesis in vitro. In this study, we examined intracellular Ca2+ movement as one of the second messengers for human hepatocyte growth factor in primary‐cultured hepatocytes. The addition of hHGF induced Ca2+ oscillation, but the frequency of oscillations varied from cell to cell.

Cytokines tumor necrosis factor and interleukin‐6 in experimental biliary obstruction in mice

M. H. A. Bemelmans, D. J. Gouma, J. W. Greve, W. A. Buurman – 1 June 1992 – The putative role of the cytokines interleukin‐6 and tumor necrosis factor in the pathophysiology of the complications and mortality after surgery in jaundiced patients was studied in a murine model. Cytokine serum levels were determined in mice with experimental biliary obstruction. As an indicator of the activation status of macrophages, cytokine release by mononuclear phagocytes obtained from such mice was assessed.

Immunolocalization, quantitation and cellular heterogeneity of apolipoprotein B in rat hepatocytes

James P. Corsetti, Barbara A. Way, Charles E. Sparks, Janet D. Sparks – 1 June 1992 – Hepatocyte autofluorescence represents a major problem in immunofluorescence studies with fluorescein conjugates because of significant spectral overlap. We describe a method for immunostaining hepatocytes with R‐phycoerythrin (a fluorochrome with minimal overlap with autofluorescence) with paraformaldehyde fixation and Triton X‐100 permeabilization for better antibody penetration.

Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver

Yorio Matsumoto, G. Alex Bishop, Geoffrey William McCaughan – 1 June 1992 – Dipeptidyl peptidase IV is a cell surface ectopeptidase with widespread tissue distribution. Recently it was shown to display extracellular matrix—binding properties; therefore its role in cirrhosis is of interest. The aim of this study was to use monoclonal antibodies directed against the human CD26 antigen (which has been shown to be dipeptidyl peptidase IV) to study the distribution of this molecule in normal human and cirrhotic liver.

Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

Joaquin Palma, Humberto Reyes, Jose Ribalta, Joaquin Iglesias, Manuel C. Gonazalez, Ismael Hernandez, Celia Alvarez, Claudina Molina, Ana Maria Danitz – 1 June 1992 – The efficacy and safety of ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy was investigated in an open pilot study. Five patients received 1 gm/day of ursodeoxycholic acid during 20 days and another three patients received two identical periods of treatment separated by a 14‐day interval free of the drug.

Subscribe to